Anti-c-erbB2-anti-CD3 bifunctional monoclonal antibodies
Alternative Names: Anti-c-erbB-2-anti-CD3-epsilon; Anti-CD3-anti-HER-2 monoclonal antibody; bifunctional antibodyLatest Information Update: 25 Sep 2021
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; ERBB 2 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Apr 1997 No-Development-Reported for Cancer in Japan (Parenteral)